Valuation dashboard for Vertex Pharmaceuticals Incorporated (VRTX) with P/E 29.38, P/B 6.21, EV/EBITDA 23.59 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene.
Analysis Summary
Vertex Pharmaceuticals Incorporated reported revenue of $12.07B in the most recent fiscal year, growing at a 5-year CAGR of 14.2%. Net income reached $3.95B, with a 7.8% 5-year CAGR.
Trailing-twelve-month margins: gross margin 85.0%, operating margin 39.4%, net margin 32.7%.
At the current price of $503.50, VRTX trades at a P/E of 29.38 and an ROE of 21.18%. Market capitalisation stands at $127.8B, placing it among large-cap names.
Balance sheet quality for VRTX: current ratio of 2.9. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 29.38 |
| Price / Book | 6.21 |
| EV / EBITDA | 23.59 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $311.69 |
| vs Current Price | -38.1% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Incorporated | $128.1B | 29.38 | 6.21 | 21.2% |
| REGN | Regeneron Pharmaceuticals, Inc. | $75.7B | 17.55 | 2.40 | 14.4% |
| ARGX | argenx SE | $57.2B | 33.53 | 6.84 | 21.7% |
| BMY | Bristol-Myers Squibb Company | $124.9B | 13.47 | 5.59 | 46.8% |
| GSK | GSK plc | $94.2B | 14.83 | 4.05 | 28.3% |
| MDT | Medtronic plc | $110.6B | 21.28 | 2.20 | 9.7% |
| HCA | HCA Healthcare, Inc. | $92.4B | 14.28 | -112.9% | |
| MCK | McKesson Corporation | $105.6B | 24.04 | -219.2% |
Price
| Price | $503.50 |
| Market Cap | $127.8B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 21.18% |
| Return on Invested Capital | 18.12% |
| Return on Assets | 15.12% |
| Gross Margin | 85.03% |
| Operating Margin | 39.43% |
| Net Margin | 32.74% |
Related companies: ARGX · BMY · CVS · GSK · HCA · MCK · MDT
Explore sector: Healthcare · Biotechnology
More sections of VRTX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks